COVID Drug May Also Ease Symptoms of Long COVID
An antiviral drug approved for high-risk COVID patients may also benefit those with long COVID, according to the findings of a small case series that need to be confirmed with future rigorous studies.
![Sick woman lying on her couch, holding a mug and a tissue](/sites/default/files/styles/news_card__image/public/2022-05/sick-woman.jpg)
University of California San Francisco
Give to UCSFAn antiviral drug approved for high-risk COVID patients may also benefit those with long COVID, according to the findings of a small case series that need to be confirmed with future rigorous studies.
In a study, UCSF neurologist William Seeley, MD, and colleagues identified two key moments in the natural history of Alzheimer’s, pointing to a window of opportunity for treatment with amyloid-lowering drugs.
55% of seniors with dementia take more than six medications even though most have good health. However, a UCSF study showed that 87% are willing to cut down if their doctors agree.
UCSF researchers successfully leveraged an FDA-approved drug to halt growth of tumors driven by mutations in the RAS gene, which are famously difficult to treat and account for about one in four cancer deaths.
Mark Moasser, MD, has sorted out why HER2, the protein driving 1 in 5 breast cancers, is so hard to drug. He explains how the findings correct a naive way of envisioning how HER2 is shaped and how it works.
Using data from over 100,000 malignant and non-malignant cells from 15 human brain metastases, UCSF researchers have revealed two functional archetypes of metastatic cells across 7 different types of brain tumors, each containing both immune and non-immune cell types.
A UCSF-led study found a new drug for ALS that shows to slow or temporarily stall the progression of ALS in a select group of patients, with three times as many patients' disease slowing compared to those who received a placebo.
In the quest for new treatments for COVID-19, a team led by UCSF researchers identified a new potential drug target that may prevent infection of human cells by SARS-CoV-2.
There is some information that is known about the variant and other information that sti
Helen Diller Family Cancer Research Building Experts from UCSF Health will present new research and clinical findings at the annual San Antonio Breast Cancer Symposium, the world’s largest and most
Hoping to discover a new approach to treating depression, UCSF researchers looked at mitochondrial proteins and found that people with untreated depression have significantly lower levels of these proteins. New hypotheses emerge about the relationship between depression and the function of the brain’s energy-hungry neurons.
A UCSF and Stanford study of electronic health records linked SSRIs, the most widely prescribed antidepressants, to survival for COVID-19 patients.
UCSF’s research has been ranked among the top in the world, according to the latest U.S. News & World Report’s Best Global Universities 2022 rankings.
Researchers at UCSF’s Quantitative Biosciences Institute (QBI) have observed how molecular switches regulate many different biological processes simultaneously. Their findings may shed light on how disease mutations operate, offering new ways to target malfunctioning switches and prevent illness.
A team of UCSF scientists have identified the specific neurons and signaling pathway that make sexually receptive females of many species more active at the time of ovulation.
Glioblastoma is the most common malignant brain tumor and among the most treatment-resistant cancers. In the last 15 years, numerous attempts to develop new drugs for glioblastoma have failed.
A clinical trial of new treatment regimens, led in part by researchers at UCSF, recently demonstrated that a more potent combination of antibiotics could shorten the duration of treatment for TB.
A team of researchers at have uncovered some intriguing clues in the mystery of how some poison birds and frogs evade their own toxins.
UCSF researchers have leveraged two new molecules, one of which is currently in clinical oncology trials, to devise a dual-drug therapy for alcohol use disorder (AUD), without the side effects or complications associated with current treatment regimens.
UCSF researchers in collaboration with the Centers for Disease Control’s Tuberculosis Trials Consortium and the AIDS Clinical Trials Group published a landmark study that demonstrated a new four-month treatment regimen for tuberculosis was safe and as efficacious as the standard six-month therapy.
A UCSF study has found that the antibiotic azithromycin was no more effective than a placebo in preventing symptoms of COVID-19 among non-hospitalized patients, and may increase their chance of hospitalization, despite widespread prescription of the antibiotic for the disease.
Taking a page from computer engineers, biologists are trying their hands at programming cells – by building DNA circuits to guide their protein-making machinery and behavior.
Plenty of probiotic yogurts, pickles and kombuchas claim to boost our digestive health with armies of microbes, but some scientists have more ambitious therapeutic plans for the “bugs” that colonize us. They hope to leverage these microbes as living therapeutics for a range of health conditions, including ulcerative colitis, multiple sclerosis, eczema and asthma.
T cells – immune cells that patrol our bodies in search of trouble – have become a central focus for UC San Francisco scientists working on living cell therapies, an approach that views cells
The B.1.1.7 coronavirus variant—also known as Alpha—may be more infectious because it contains mutations that make it better adapted to foil the innate immune system, at least for long enough to allow the virus to replicate and potentially find new hosts, according to a new study.